Evotec stock at EUR 3.23, up 2.22% pre-market
Published on 11/12/2026 at 08:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEvotec business and market setup
- Evotec combines drug research with advanced technology, science and AI-driven innovation in partnerships.
- Just - Evotec Biologics and milestone-based partnerships are central elements of the company's growth strategy.
Evotec stock traded at EUR 3.23 on Lang & Schwarz at 07:58 CET on Thursday, November 12, 2026, 2.22% above the Xetra close of Wednesday, November 11, 2026, at EUR 3.16.
Evotec says its business combines advanced technologies, scientific research and AI-driven innovation with partnerships to accelerate the path from drug concept to treatment. The company uses molecular patient data, patient-based disease models and omics-supported drug research as elements of this approach. Evotec's investor-relations page identifies technology, operational excellence and a pipeline supported by partners as pillars of its equity story.
Growth depends on partnerships
Just - Evotec Biologics is described as a catalyst for profitable growth, with a focus on monetizing technologies and production assets. Evotec also highlights milestone payments, licensing income and potential revenue shares as components of more complex customer relationships and long-term partnerships.
The company's model combines research services, technology platforms and development and manufacturing capabilities. For investors, the mix leaves partnership activity, pipeline milestones and the execution of the Biologics strategy as key areas to watch.
The broader German market environment can be followed in the DAX.
